Medicines and vaccines
Search documents
Jim Cramer on Pfizer: “I’m Going to Say Just Weak Hold”
Yahoo Finance· 2025-12-21 15:07
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on. During the lightning round, a caller sought Cramer’s opinion on the stock, and he said: “Okay, Pfizer, really good yield, not a lot of momentum. Didn’t like the update yesterday. I’m going to say just weak hold.” Photo by Spencer Davis on Unsplash Pfizer Inc. (NYSE:PFE) creates and sells medicines and vaccines for several health conditions, including heart disease, infections, COVID-19, and rare diseases. Cramer was asked about the ...
Jim Cramer on Pfizer: “I Would Hold on to It”
Yahoo Finance· 2025-12-04 05:05
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think Dr. Bourla is going to trace things out in January at the JPMorgan conference. I think you might like what you hear… 6.8% yield. Until then, I would hold onto it. That’s my, I would hold on to it.” Photo by Spencer ...
Jim Cramer Says Pfizer “Will Continue to Sell at Eight Times Earnings”
Yahoo Finance· 2025-11-07 03:21
Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a buy. In response, Cramer said: “No. Pfizer sells at eight times earnings and will continue to sell at eight times earnings. I’ll give you an example of what Dr. Bourla shou ...
Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”
Yahoo Finance· 2025-11-03 16:06
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with a 7% yield, not much price appreciation. I like growth, but that dividend seems safe, and it’s backed up by cash flow. On Tuesday morning, we’ll find out if Pfizer’s going to be more of a stock and less ...